These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 26688076)

  • 1. A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation.
    Hatzoglou V; Yang TJ; Omuro A; Gavrilovic I; Ulaner G; Rubel J; Schneider T; Woo KM; Zhang Z; Peck KK; Beal K; Young RJ
    Neuro Oncol; 2016 Jun; 18(6):873-80. PubMed ID: 26688076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effectiveness of MRI perfusion and fluorine-18 FDG PET-CT for differentiating radiation injury from viable brain tumor: a preliminary retrospective analysis with pathologic correlation in all patients.
    Hatzoglou V; Ulaner GA; Zhang Z; Beal K; Holodny AI; Young RJ
    Clin Imaging; 2013; 37(3):451-7. PubMed ID: 23068052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of FDG-PET/MRI, FDG-PET/CT, and Dynamic Susceptibility Contrast Perfusion MRI in Differentiating Radiation Necrosis from Tumor Recurrence in Glioblastomas.
    Hojjati M; Badve C; Garg V; Tatsuoka C; Rogers L; Sloan A; Faulhaber P; Ros PR; Wolansky LJ
    J Neuroimaging; 2018 Jan; 28(1):118-125. PubMed ID: 28718993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
    Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
    Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated PET-MRI for Glioma Surveillance: Perfusion-Metabolism Discordance Rate and Association With Molecular Profiling.
    Seligman L; Kovanlikaya I; Pisapia DJ; Naeger DM; Magge R; Fine HA; Chiang GC
    AJR Am J Roentgenol; 2019 Apr; 212(4):883-891. PubMed ID: 30779663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective comparative diagnostic accuracy evaluation of dynamic contrast-enhanced (DCE) vs. dynamic susceptibility contrast (DSC) MR perfusion in differentiating tumor recurrence from radiation necrosis in treated high-grade gliomas.
    Zakhari N; Taccone MS; Torres CH; Chakraborty S; Sinclair J; Woulfe J; Jansen GH; Cron GO; Thornhill RE; McInnes MDF; Nguyen TB
    J Magn Reson Imaging; 2019 Aug; 50(2):573-582. PubMed ID: 30614146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
    Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
    Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Dynamic Susceptibility Contrast Perfusion-Weighted MR Imaging and
    Qiao Z; Zhao X; Wang K; Zhang Y; Fan D; Yu T; Shen H; Chen Q; Ai L
    AJNR Am J Neuroradiol; 2019 Feb; 40(2):253-259. PubMed ID: 30655259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accurate differentiation of recurrent gliomas from radiation injury by kinetic analysis of α-11C-methyl-L-tryptophan PET.
    Alkonyi B; Barger GR; Mittal S; Muzik O; Chugani DC; Bahl G; Robinette NL; Kupsky WJ; Chakraborty PK; Juhász C
    J Nucl Med; 2012 Jul; 53(7):1058-64. PubMed ID: 22653792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Narrow interval dual phase 18F-FDG PET/CT: A practical approach for distinguishing tumor recurrence from radiation necrosis in brain metastasis.
    Aggarwal A; Aggarwal AK; Prakash S; Vile DJ; Aggarwal A
    Medicine (Baltimore); 2024 May; 103(18):e37789. PubMed ID: 38701250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioma Recurrence Versus Radiation Necrosis: Single-Session Multiparametric Approach Using Simultaneous O-(2-18F-Fluoroethyl)-L-Tyrosine PET/MRI.
    Jena A; Taneja S; Gambhir A; Mishra AK; Dʼsouza MM; Verma SM; Hazari PP; Negi P; Jhadav GK; Sogani SK
    Clin Nucl Med; 2016 May; 41(5):e228-36. PubMed ID: 26859208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of (11)C-methionine, (11)C-choline, and (18)F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis.
    Takenaka S; Asano Y; Shinoda J; Nomura Y; Yonezawa S; Miwa K; Yano H; Iwama T
    Neurol Med Chir (Tokyo); 2014; 54(4):280-9. PubMed ID: 24305028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ASL, DSC, DCE perfusion MRI and 18F-DOPA PET/CT in differentiating glioma recurrence from post-treatment changes.
    Moltoni G; Romano A; Capriotti G; Campagna G; Ascolese AM; Romano A; Dellepiane F; Minniti G; Signore A; Bozzao A
    Radiol Med; 2024 Sep; 129(9):1382-1393. PubMed ID: 39117936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of effects of 18F-FDG PET-CT and MRI in identifying and grading gliomas.
    Song PJ; Lu QY; Li MY; Li X; Shen F
    J Biol Regul Homeost Agents; 2016; 30(3):833-838. PubMed ID: 27655507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI.
    Kim YH; Oh SW; Lim YJ; Park CK; Lee SH; Kang KW; Jung HW; Chang KH
    Clin Neurol Neurosurg; 2010 Nov; 112(9):758-65. PubMed ID: 20619531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating between Central Nervous System Lymphoma and High-grade Glioma Using Dynamic Susceptibility Contrast and Dynamic Contrast-enhanced MR Imaging with Histogram Analysis.
    Murayama K; Nishiyama Y; Hirose Y; Abe M; Ohyu S; Ninomiya A; Fukuba T; Katada K; Toyama H
    Magn Reson Med Sci; 2018 Jan; 17(1):42-49. PubMed ID: 28515410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation between intra-axial metastatic tumor progression and radiation injury following fractionated radiation therapy or stereotactic radiosurgery using MR spectroscopy, perfusion MR imaging or volume progression modeling.
    Huang J; Wang AM; Shetty A; Maitz AH; Yan D; Doyle D; Richey K; Park S; Pieper DR; Chen PY; Grills IS
    Magn Reson Imaging; 2011 Sep; 29(7):993-1001. PubMed ID: 21571478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
    Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic accuracy of dynamic gadoxetic-acid-enhanced MRI and PET/CT compared in patients with liver metastases from neuroendocrine neoplasms.
    Armbruster M; Zech CJ; Sourbron S; Ceelen F; Auernhammer CJ; Rist C; Haug A; Singnurkar A; Reiser MF; Sommer WH
    J Magn Reson Imaging; 2014 Aug; 40(2):457-66. PubMed ID: 24347148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is integrated 18F-FDG PET/MRI superior to 18F-FDG PET/CT in the differentiation of incidental tracer uptake in the head and neck area?
    Schaarschmidt BM; Gomez B; Buchbender C; Grueneisen J; Nensa F; Sawicki LM; Ruhlmann V; Wetter A; Antoch G; Heusch P
    Diagn Interv Radiol; 2017; 23(2):127-132. PubMed ID: 28089955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.